1
|
Wang H, Clapp B, Hoffman C, Yang X, Pascual DW. A Single Nasal Dose Vaccination with a Brucella abortus Mutant Potently Protects against Pulmonary Infection. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2023; 210:1576-1588. [PMID: 37036290 PMCID: PMC10159994 DOI: 10.4049/jimmunol.2300071] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 03/14/2023] [Indexed: 04/11/2023]
Abstract
The Brucella abortus double-mutant (ΔznuA ΔnorD Brucella abortus-lacZ [znBAZ]) was assessed for its protective efficacy after vaccination with a single nasal dose. Superior protection was achieved in znBAZ-vaccinated mice against pulmonary, wild-type B. abortus 2308 challenge when compared with conventional livestock Brucella abortus vaccines, the smooth S19 (smooth B. abortus strain 19 vaccine) and rough RB51 (rough mutant vaccine strain of B. abortus) strains. Nasal znBAZ vaccination reduced splenic and lung colonization by wild-type brucellae by >3-4 logs. In contrast, S19 reduced lung colonization by only 32-fold, and RB51 failed to reduce colonization. One profound attribute of znBAZ vaccination was the >3-fold increase in pulmonary CD8+ T cells when compared with other vaccinated groups. S19 vaccination increased only CD4+ T cells. All vaccines induced IFN-γ and TNF-α production by CD4+ T cells, but only znBAZ vaccination enhanced the recruitment of polyfunctional CD8+ T cells, by >100-fold. IL-17 by both CD4+ and CD8+ T cells was also induced by subsequent znBAZ vaccination. These results demonstrate that, in addition to achieving protective immunity by CD4+ T cells, CD8+ T cells, specifically resident memory T cells, also confer protection against brucellosis. The protection obtained by znBAZ vaccination was attributed to IFN-γ-producing CD8+ T cells, because depletion of CD8+ T cells throughout vaccination and challenge phases abrogated protection. The stimulation of only CD4+ T cells by RB51- and S19-vaccinated mice proved insufficient in protecting against pulmonary B. abortus 2308 challenge. Thus, nasal znBAZ vaccination offers an alternative means to elicit protection against brucellosis.
Collapse
Affiliation(s)
- Hongbin Wang
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL
| | - Beata Clapp
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL
| | - Carol Hoffman
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL
| | - Xinghong Yang
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL
| | - David W. Pascual
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL
| |
Collapse
|
2
|
Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs. BIOMED RESEARCH INTERNATIONAL 2020; 2020:1438928. [PMID: 33274194 PMCID: PMC7695499 DOI: 10.1155/2020/1438928] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 09/10/2020] [Accepted: 10/15/2020] [Indexed: 01/18/2023]
Abstract
In this paper, we first used recombinant influenza viral vector (rIVV) subtype H5N1 expressing from the open reading frame of NS1 80 and NS1 124 amino acids of Brucella outer membrane proteins (Omp) 16 and 19, ribosomal L7/L12, and Cu-Zn superoxide dismutase (SOD) proteins to develop a human brucellosis vaccine. We made 18 combinations of IVVs in mono-, bi-, and tetravalent vaccine formulations and tested them on mice to select the safest and most effective vaccine samples. Then, the most effective vaccine candidates were further tested on guinea pigs. Safety of the rIVV-based vaccine candidate was evaluated by a mouse weight-gain test. Mice and guinea pigs were challenged with the virulent strain B. melitensis 16M. The protective effect of the rIVV-based vaccine candidate was assessed by quantitation of Brucella colonization in tissues and organs of challenged animals. All vaccine formulations were safe in mice. Tested vaccine formulations, as well as the commercial B. melitensis Rev.1 vaccine, have been found to protect mice from B. melitensis 16M infection within the range of 1.6 to 2.97 log10 units (P < 0.05). Tetravalent vaccine formulations from the position of NS1 80 amino acids (0.2 ± 0.4), as well as the commercial B. melitensis Rev.1 vaccine (1.2 ± 2.6), have been found to protect guinea pigs from B. melitensis 16M infection at a significant level (P < 0.05). Thus, tetravalent vaccine formulation Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD was chosen as a potential vaccine candidate for further development of an effective human vaccine against brucellosis. These results show a promising future for the development of a safe human vaccine against brucellosis based on rIVVs.
Collapse
|
3
|
Wang H, Hoffman C, Yang X, Clapp B, Pascual DW. Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection. PLoS Pathog 2020; 16:e1008176. [PMID: 31951645 PMCID: PMC6968852 DOI: 10.1371/journal.ppat.1008176] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Accepted: 10/31/2019] [Indexed: 12/15/2022] Open
Abstract
Brucellosis remains the most common zoonotic disease globally. Currently no vaccines for humans exist, and conventional brucellosis vaccines for livestock fail to confer complete protection; hence, an improved vaccine is needed. Although Brucella infections primarily occur following a mucosal exposure, vaccines are administered parenterally. Few studies have considered mucosal vaccinations, or even targeting of tissue-resident memory T (TRM) cells. TRM cells protect against viral infections, but less is known of their role in bacterial infections, and even less for brucellosis. Oral prime, nasal boost with a newly developed Brucella abortus double mutant (znBAZ) confers nearly complete protection against pulmonary challenge with wild-type (wt) B. abortus 2308, and its protective efficacy is >2800-fold better than the RB51 vaccine. Vaccination with znBAZ potently stimulated CD8+ T cells, whereas mucosal vaccination with RB51 induced mostly CD4+ T cells. Subsequent analysis revealed these pulmonary CD44+ CD69+ CD8+ T cells to be either CD103+ or CD103- TRM cells, and these sequestered to the lung parenchyma as CXCR3lo and to the airways as CXCR3hi. Both CD8+ TRM subsets contained single-positive IFN-γ and TNF-α, as well as, polyfunctional cells. IL-17-producing CD8+ TRM cells were also induced by znBAZ vaccination, but in vivo IL-17 neutralization had no impact upon protection. In vivo depletion of CD4+ T cells had no impact upon protection in znBAZ-vaccinated mice. In contrast, CD4+ T cell depletion reduced RB51’s protective efficacy in spleens and lungs by two- and three-logs, respectively. Although anti-CD8 mAb-treated znBAZ-vaccinated mice showed a significantly reduced pulmonary efficacy, this treatment failed to completely deplete the lung CD8+ T cells, leaving the CD103+ and CD103- CD8+ TRM cell ratios intact. Only znBAZ-vaccinated CD8-/- mice were fully sensitive to pulmonary challenge with virulent wt B. abortus 2308 since CD8+ TRM cells could not be induced. Collectively, these data demonstrate the key role of mucosal vaccination for the generation of CD8+ TRM cells in protecting against pulmonary challenge with virulent B. abortus. Brucellosis is the most common zoonotic disease worldwide and is transmitted via the consumption of unpasteurized dairy products or exposure to Brucella-laden aerosols. In fact, mucosal exposure is the most common route of infection for humans and animals, yet parenteral vaccination of livestock remains the preferred route of immunization. To determine whether development of a mucosal vaccination regimen could effectively generate immunity against pulmonary challenge with virulent B. abortus, a double-mutant B. abortus vaccine was administered mucosally, and found to induce CD8+ TRM cells. These conferred complete protection against pulmonary infection and prevented systemic brucellae spread even in the absence of immune recirculating CD8+ T cells. These data show that mucosal vaccination can stimulate the induction of TRM cells, which should be considered as a more effective means to protect against brucellosis. Furthermore, brucellosis needs to be considered a mucosal pathogen to warrant development of approaches different from conventional methods to protect humans and livestock against this disease.
Collapse
Affiliation(s)
- Hongbin Wang
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America
| | - Carol Hoffman
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America
| | - Xinghong Yang
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America
| | - Beata Clapp
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America
| | - David W. Pascual
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America
- * E-mail:
| |
Collapse
|
4
|
Dorneles EMS, Lima GK, Teixeira-Carvalho A, Araújo MSS, Martins-Filho OA, Sriranganathan N, Al Qublan H, Heinemann MB, Lage AP. Immune Response of Calves Vaccinated with Brucella abortus S19 or RB51 and Revaccinated with RB51. PLoS One 2015; 10:e0136696. [PMID: 26352261 PMCID: PMC4564183 DOI: 10.1371/journal.pone.0136696] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 08/05/2015] [Indexed: 12/28/2022] Open
Abstract
Brucella abortus S19 and RB51 strains have been successfully used to control bovine brucellosis worldwide; however, currently, most of our understanding of the protective immune response induced by vaccination comes from studies in mice. The aim of this study was to characterize and compare the immune responses induced in cattle prime-immunized with B. abortus S19 or RB51 and revaccinated with RB51. Female calves, aged 4 to 8 months, were vaccinated with either vaccine S19 (0.6-1.2 x 1011 CFU) or RB51 (1.3 x 1010 CFU) on day 0, and revaccinated with RB51 (1.3 x 1010 CFU) on day 365 of the experiment. Characterization of the immune response was performed using serum and peripheral blood mononuclear cells. Blood samples were collected on days 0, 28, 210, 365, 393 and 575 post-immunization. Results showed that S19 and RB51 vaccination induced an immune response characterized by proliferation of CD4+ and CD8+ T-cells; IFN-ɣ and IL-17A production by CD4+ T-cells; cytotoxic CD8+ T-cells; IL-6 secretion; CD4+ and CD8+ memory cells; antibodies of IgG1 class; and expression of the phenotypes of activation in T-cells. However, the immune response stimulated by S19 compared to RB51 showed higher persistency of IFN-ɣ and CD4+ memory cells, induction of CD21+ memory cells and higher secretion of IL-6. After RB51 revaccination, the immune response was chiefly characterized by increase in IFN-ɣ expression, proliferation of antigen-specific CD4+ and CD8+ T-cells, cytotoxic CD8+ T-cells and decrease of IL-6 production in both groups. Nevertheless, a different polarization of the immune response, CD4+- or CD8+-dominant, was observed after the booster with RB51 for S19 and RB51 prime-vaccinated animals, respectively. Our results indicate that after prime vaccination both vaccine strains induce a strong and complex Th1 immune response, although after RB51 revaccination the differences between immune profiles induced by prime-vaccination become accentuated.
Collapse
Affiliation(s)
- Elaine M. S. Dorneles
- Laboratório de Bacteriologia Aplicada, Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Graciela K. Lima
- Laboratório de Bacteriologia Aplicada, Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Andréa Teixeira-Carvalho
- Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil
| | - Márcio S. S. Araújo
- Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil
| | - Olindo A. Martins-Filho
- Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil
| | - Nammalwar Sriranganathan
- Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America
| | - Hamzeh Al Qublan
- Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America
| | - Marcos B. Heinemann
- Departamento de Medicina Veterinária Preventiva e Saúde Animal, Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Andrey P. Lage
- Laboratório de Bacteriologia Aplicada, Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| |
Collapse
|
5
|
Dorneles EMS, Sriranganathan N, Lage AP. Recent advances in Brucella abortus vaccines. Vet Res 2015; 46:76. [PMID: 26155935 PMCID: PMC4495609 DOI: 10.1186/s13567-015-0199-7] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2014] [Accepted: 05/05/2015] [Indexed: 01/18/2023] Open
Abstract
Brucella abortus vaccines play a central role in bovine brucellosis control/eradication programs and have been successfully used worldwide for decades. Strain 19 and RB51 are the approved B. abortus vaccines strains most commonly used to protect cattle against infection and abortion. However, due to some drawbacks shown by these vaccines much effort has been undertaken for the development of new vaccines, safer and more effective, that could also be used in other susceptible species of animals. In this paper, we present a review of the main aspects of the vaccines that have been used in the brucellosis control over the years and the current research advances in the development of new B. abortus vaccines.
Collapse
Affiliation(s)
- Elaine M S Dorneles
- Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Laboratório de Bacteriologia Aplicada, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
| | - Nammalwar Sriranganathan
- Department of Biomedical Sciences and Pathobiology, Center for Molecular Medicine and Infectious Diseases, Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
| | - Andrey P Lage
- Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Laboratório de Bacteriologia Aplicada, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
| |
Collapse
|
6
|
Dorneles EMS, Teixeira-Carvalho A, Araújo MSS, Sriranganathan N, Lage AP. Immune response triggered by Brucella abortus following infection or vaccination. Vaccine 2015; 33:3659-66. [PMID: 26048781 DOI: 10.1016/j.vaccine.2015.05.057] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Revised: 05/16/2015] [Accepted: 05/21/2015] [Indexed: 01/18/2023]
Abstract
Brucella abortus live vaccines have been used successfully to control bovine brucellosis worldwide for decades. However, due to some limitations of these live vaccines, efforts are being made for the development of new safer and more effective vaccines that could also be used in other susceptible species. In this context, understanding the protective immune responses triggered by B. abortus is critical for the development of new vaccines. Such understandings will enhance our knowledge of the host/pathogen interactions and enable to develop methods to evaluate potential vaccines and innovative treatments for animals or humans. At present, almost all the knowledge regarding B. abortus specific immunological responses comes from studies in mice. Active participation of macrophages, dendritic cells, IFN-γ producing CD4(+) T-cells and cytotoxic CD8(+) T-cells are vital to overcome the infection. In this review, we discuss the characteristics of the immune responses triggered by vaccination versus infection by B. abortus, in different hosts.
Collapse
Affiliation(s)
- Elaine M S Dorneles
- Laboratório de Bacteriologia Aplicada, Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, 31270-901, Belo Horizonte, Minas Gerais, Brazil
| | - Andréa Teixeira-Carvalho
- Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Avenida Augusto de Lima 1715, 30190-002, Belo Horizonte, Minas Gerais, Brazil
| | - Márcio S S Araújo
- Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Avenida Augusto de Lima 1715, 30190-002, Belo Horizonte, Minas Gerais, Brazil
| | - Nammalwar Sriranganathan
- Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, 1410 Prices Fork Rd, Blacksburg, VA 24061, USA
| | - Andrey P Lage
- Laboratório de Bacteriologia Aplicada, Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
| |
Collapse
|
7
|
Liu Y, Islam EA, Jarvis GA, Gray-Owen SD, Russell MW. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal Immunol 2012; 5:320-31. [PMID: 22354319 PMCID: PMC3328619 DOI: 10.1038/mi.2012.12] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Infection with Neisseria gonorrhoeae does not induce specific immunity or immune memory. Our previous studies in a murine model of vaginal gonococcal infection showed that innate immunity governed by Th17 cells was a critical aspect of the immune response elicited by this pathogen. Herein we show that N. gonorrhoeae selectively inhibited Th1 and Th2 cells and enhanced Th17 cell development through the induction of TGF-β. Whereas Th17 responses depended on gonococcal lipooligosaccharide acting through TLR4, the inhibitory effect of N. gonorrhoeae on Th1/Th2 responses involved gonococcal Opa proteins. In vitro Th17 responses to N. gonorrhoeae could be diverted to Th1/Th2 by blockade of TGF-β, but not by blockade of IL-17. The results reveal that N. gonorrhoeae suppresses Th1/Th2-mediated adaptive immune response through mechanisms dependent on TGF-β, and that this effect can be manipulated to promote the development of adaptive immunity.
Collapse
Affiliation(s)
- Yingru Liu
- Department of Microbiology and Immunology, and Witebsky Center for Microbial Pathogenesis and Immunology, University at Buffalo, Buffalo, NY 14214, USA
| | - Epshita A. Islam
- Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Gary A. Jarvis
- Center for Immunochemistry, Veterans Affairs Medical Center, San Francisco, CA, 94121; and Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Scott D. Gray-Owen
- Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Michael W. Russell
- Department of Microbiology and Immunology, and Witebsky Center for Microbial Pathogenesis and Immunology, University at Buffalo, Buffalo, NY 14214, USA
| |
Collapse
|
8
|
Fu S, Xu J, Li X, Xie Y, Qiu Y, Du X, Yu S, Bai Y, Chen Y, Wang T, Wang Z, Yu Y, Peng G, Huang K, Huang L, Wang Y, Chen Z. Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection. PLoS One 2012; 7:e29552. [PMID: 22383953 PMCID: PMC3286461 DOI: 10.1371/journal.pone.0029552] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Accepted: 11/30/2011] [Indexed: 01/18/2023] Open
Abstract
Due to drawbacks of live attenuated vaccines, much more attention has been focused on screening of Brucella protective antigens as subunit vaccine candidates. Brucella is a facultative intracellular bacterium and cell mediated immunity plays essential roles for protection against Brucella infection. Identification of Brucella antigens that present T-cell epitopes to the host could enable development of such vaccines. In this study, 45 proven or putative pathogenesis-associated factors of Brucella were selected according to currently available data. After expressed and purified, 35 proteins were qualified for analysis of their abilities to stimulate T-cell responses in vitro. Then, an in vitro gamma interferon (IFN-γ) assay was used to identify potential T-cell antigens from B. abortus. In total, 7 individual proteins that stimulated strong IFN-γ responses in splenocytes from mice immunized with B. abortus live vaccine S19 were identified. The protective efficiencies of these 7 recombinant proteins were further evaluated. Mice given BAB1_1316 (CobB) or BAB1_1688 (AsnC) plus adjuvant could provide protection against virulent B. abortus infection, similarly with the known protective antigen Cu-Zn SOD and the license vaccine S19. In addition, CobB and AsnC could induce strong antibodies responses in BALB/c mice. Altogether, the present study showed that CobB or AsnC protein could be useful antigen candidates for the development of subunit vaccines against brucellosis with adequate immunogenicity and protection efficacy.
Collapse
Affiliation(s)
- Simei Fu
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- School of Public Health, Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun, China
| | - Jie Xu
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- School of Public Health, Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun, China
| | - Xianbo Li
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- College of Veterinary Medicine, Sichuan Agricultural University, Ya'an, China
| | - Yongfei Xie
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
| | - Yefeng Qiu
- Experimental Animal Center, Academy of Military Medical Science, Beijing, China
| | - Xinying Du
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
| | - Shuang Yu
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
| | - Yaoxia Bai
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
| | - Yanfen Chen
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- School of Public Health, Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun, China
| | - Tongkun Wang
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
| | - Zhoujia Wang
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
| | - Yaqing Yu
- School of Public Health, Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun, China
| | - Guangneng Peng
- College of Veterinary Medicine, Sichuan Agricultural University, Ya'an, China
| | - Kehe Huang
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
| | - Liuyu Huang
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
| | - Yufei Wang
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- * E-mail: (YW); (ZC)
| | - Zeliang Chen
- Department of Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China
- * E-mail: (YW); (ZC)
| |
Collapse
|
9
|
Yang Y, Wang L, Yin J, Wang X, Cheng S, Lang X, Wang X, Qu H, Sun C, Wang J, Zhang R. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol 2011; 49:175-84. [DOI: 10.1016/j.molimm.2011.08.009] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2011] [Revised: 08/11/2011] [Accepted: 08/11/2011] [Indexed: 01/18/2023]
|
10
|
Yang Y, Yin J, Guo D, Lang X, Wang X. Immunization of mice with recombinantS-adenosyl-l-homocysteine hydrolase protein confers protection againstBrucella melitensisinfection. ACTA ACUST UNITED AC 2011; 61:159-67. [DOI: 10.1111/j.1574-695x.2010.00758.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Al-Mariri A. Protection of BALB/c mice against Brucella melitensis 16M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Vaccine 2010; 28:1766-70. [DOI: 10.1016/j.vaccine.2009.12.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2009] [Revised: 11/25/2009] [Accepted: 12/07/2009] [Indexed: 11/17/2022]
|
12
|
Cheng S, Jiao XD, Zhang M, Sun L. Analysis of the vaccine potential of a laboratory Escherichia coli strain in a Japanese flounder model. FISH & SHELLFISH IMMUNOLOGY 2010; 28:275-280. [PMID: 19900558 DOI: 10.1016/j.fsi.2009.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2009] [Revised: 10/24/2009] [Accepted: 11/02/2009] [Indexed: 05/28/2023]
Abstract
Escherichia coli DH5alpha is a genetically tailored laboratory strain that is commonly used for general cloning. In this study, the vaccine potential of DH5alpha was investigated. It was found that when used as a live vaccine, DH5alpha could afford effective protection upon Japanese flounder against Aeromonas hydrophila infection. Vaccination with purified outer membrane proteins and lipopolysaccharides of DH5alpha failed to induce protective immunity against A. hydrophila. Specific antibody production was observed in fish immunized with DH5alpha, which lasted at least 8 weeks and was enhanced by a booster injection during the vaccination process. Analysis of the transcription profiles of immune-related genes showed that vaccination with DH5alpha heightened the expression of the genes encoding factors that are likely involved in both specific and nonspecific immunities. Furthermore, compared to the control fish, fish vaccinated with DH5alpha/pAQ1, which is DH5alpha harboring the plasmid pAQ1 that expresses the coding element of a Vibrio harveyi antigen, exhibited significantly improved survival rates following V. harveyi and A. hydrophila challenges. These results demonstrate that DH5alpha possesses intrinsic immunoprotective potential against A. hydrophila. This property, together with the feature of cloning friendliness, should render DH5alpha useful in the construction of cross-protective vaccines.
Collapse
Affiliation(s)
- Shuang Cheng
- Institute of Oceanology, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, PR China
| | | | | | | |
Collapse
|
13
|
Abstract
There is currently no licensed vaccine for brucellosis in humans. Available animal vaccines may cause disease and are considered unsuitable for use in humans. However, the causative pathogen, Brucella, is among the most common causes of laboratory-acquired infections and is a Center for Disease Control category B select agent. Thus, human vaccines for brucellosis are required. This review highlights the considerations that are needed in the journey to develop a human vaccine, including animal models, and includes an assessment of the current status of novel vaccine candidates.
Collapse
Affiliation(s)
- Stuart D Perkins
- Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire, UK
| | | | | |
Collapse
|
14
|
Characterization of DegQVh, a serine protease and a protective immunogen from a pathogenic Vibrio harveyi strain. Appl Environ Microbiol 2008; 74:6254-62. [PMID: 18723647 DOI: 10.1128/aem.00109-08] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Vibrio harveyi is an important marine pathogen that can infect a number of aquaculture species. V. harveyi degQ (degQ(Vh)), the gene encoding a DegQ homologue, was cloned from T4, a pathogenic V. harveyi strain isolated from diseased fish. DegQ(Vh) was closely related to the HtrA family members identified in other Vibrio species and could complement the temperature-sensitive phenotype of an Escherichia coli strain defective in degP. Expression of degQ(Vh) in T4 was modulated by temperature, possibly through the sigma(E)-like factor. Enzymatic analyses demonstrated that the recombinant DegQ(Vh) protein expressed in and purified from E. coli was an active serine protease whose activity required the integrity of the catalytic site and the PDZ domains. The optimal temperature and pH of the recombinant DegQ(Vh) protein were 50 degrees C and pH 8.0. A vaccination study indicated that the purified recombinant DegQ(Vh) was a protective immunogen that could confer protection upon fish against infection by V. harveyi. In order to improve the efficiency of DegQ(Vh) as a vaccine, a genetic construct in the form of the plasmid pAQ1 was built, in which the DNA encoding the processed DegQ(Vh) protein was fused with the DNA encoding the secretion region of AgaV, an extracellular beta-agarase. The E. coli strain harboring pAQ1 could express and secrete the chimeric DegQ(Vh) protein into the culture supernatant. Vaccination of fish with viable E. coli expressing chimeric degQ(Vh) significantly (P < 0.001) enhanced the survival of fish against V. harveyi challenge, which was possibly due to the relatively prolonged exposure of the immune system to the recombinant antigen produced constitutively, albeit at a gradually decreasing level, by the carrier strain.
Collapse
|